29+ min ago  (85+ words) A theory-driven paper planner combined with a digital AI companion demonstrated high acceptability and improved treatment confidence among patients with metastatic TNBC initiating ADC therapy. Seth A. Wander, MD, Ph D; Kate Baxstrom, MD Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD;…...

1+ hour, 19+ min ago  (272+ words) TRIDENT failed to show an OS benefit for TTFields started during chemoradiation vs the maintenance-phase approach in newly diagnosed glioblastoma. The phase 3 TRIDENT trial (NCT04471844) did not meet its primary end point of overall survival (OS) when Tumor Treating Fields (TTFields)…...

4+ hour, 49+ min ago  (276+ words) Findings from the phase 3 SUNMO trial support the regulatory decision regarding the mosunetuzumab-based regimen for this relapsed/refractory population. The FDA has accepted a supplemental biologics license application (s BLA) for a subcutaneous formulation of mosunetuzumab (Lunsumio VELO) in combination…...

8+ hour, 7+ min ago  (445+ words) A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma. Release Date: May 6, 2026 Expiration Date: May 6, 2027 Upon successful completion of this activity, you should be better prepared to: Physicians" Education Resource, LLC, designates this…...

9+ hour, 4+ min ago  (111+ words) Sherry Shen, MD, discussed broader clinical data on GLP-1 agonists, highlighting how their positive impacts on glycemic control, lipid profiles, and cardiac health contribute to improved overall survival rates for patients with breast cancer. Shen is a medical oncologist and…...

19+ hour, 6+ min ago  (123+ words) Yan Leyfman, MD, broke down a review article titled "Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma, which was published in the journal ONCOLOGY in May 2026. He posits that among all the questions being asked in the hematology-oncology space,…...

19+ hour, 30+ min ago  (323+ words) Genitourinary (GU) cancer research continues to evolve quickly, with new data on antibody-drug conjugates (ADCs), immunotherapy combinations, and bladder-sparing strategies presented across the treatment continuum at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Cancer Network" spoke with Eric…...

20+ hour, 26+ min ago  (167+ words) In this Florida Cancer Data System analysis, structural racism and health insurance disadvantage together mediated nearly 8% of the racial disparity in TNBC between Black and White women. Black women experience disproportionately high rates of triple-negative breast cancer (TNBC), an aggressive…...

20+ hour, 27+ min ago  (189+ words) In this Florida Cancer Data System mediation analysis, racialized economic segregation and insurance disadvantage explained 29% of the racial disparity in advanced breast cancer stage at diagnosis between Black and White women. Black women in the United States experience disproportionately high…...

21+ hour, 1+ min ago  (83+ words) Updated NCCN guidelines for CNS cancers now recommend CSF-based tumor-derived DNA testing for patients with biopsy-infeasible high-grade glioma or glioblastoma. Seth A. Wander, MD, Ph D; Kate Baxstrom, MD Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, Ph D…...